Stay updated on FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Sign up to get notified when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.

Latest updates to the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page
- Check3 days agoChange DetectedB-cell chronic lymphocytic leukemia was added to the list of conditions in the study details. This expands the study description to include CLL cohorts.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check24 days agoChange DetectedRevision metadata updated: v3.4.3 added and v3.4.2 removed; no substantive content on the page was changed.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.4.2 was added, and the prior v3.4.1 notice about government funding lapse was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check59 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH Clinical Center status was added, and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check67 days agoChange DetectedAdded a 'Show glossary' option and updated several footer labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0 replacing v3.3.4). Core study information, eligibility criteria, outcomes, and study timelines remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.